Navigation Links
Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
Date:3/10/2009

SAN DIEGO, March 10 /PRNewswire/ -- Avineuro Pharmaceuticals, Inc. announced today an initiation of Phase I clinical studies of AVN-211, a potent and selective small molecule antagonist of 5-HT6 receptor for treatment of Schizophrenia. The results of Phase I studies are expected to be available in April 2009. Based on these and other results, Avineuro Pharmaceuticals, Inc. plans to advance AVN-211 into Phase II clinical trials in Q2 2009. Avineuro Pharmaceuticals, Inc. will present at the 9th International Conference - AD/PD 2009 - Prague, Czech Republic, March 11-15, 2009.

About Avineuro Pharmaceuticals, Inc.:

Avineuro discovers and develops novel small molecules for unmet medical needs in neurology and psychiatry. Avineuro emphasizes a rational approach to drug discovery that combines modern medicinal chemistry with streamlined pre-clinical and clinical development studies, thus allowing a fast transition to proof-of-concept product candidates.


'/>"/>
SOURCE Avineuro Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...BEDFORD,Mass.,Nov.25/PRNewswire-FirstCall/--Hologi...gdeveloper,manufacturerandsupplierofpremiumdiagnos...atedtoservingthehealthcareneedsofwomen,isusingthea...(RSNA)atMcCormickPlaceinChicago,November29throughD...ultimodalitydiagnosticmammographyworkstationsoftwa...
(Date:11/25/2009)...EXTON,Pa.,Nov.25/PRNewswire/--BioTrendsResearchGro...elara report,thefirstinamulti-phasesyndicatedmark...Biotech,sStelara,fromproductlaunchthroughthefirsts...quantitativeinformationfrom75uniqueDermatologistsa...assesstrialanduseofStelara,obstaclestouse,typicalp...
(Date:11/25/2009)...RANCHOCORDOVA,Calif.,Nov.25/PRNewswire/--AMPACFine...oration(Nasdaq: APFC )announcedtodaythatitreceived...rdattheAnnualStatewideEnvironmentalSummit,sponsore...ion(CMTA),theIndustrialEnvironmentalAssociation(IE...eldinSanDiego.Thisisthemostprestigiousawardavailab...
Breaking Medicine Technology:New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 3Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2Mothers Immune System May Block Fetal Treatments for Blood Diseases 54639 1Mothers Immune System May Block Fetal Treatments for Blood Diseases 54639 2Mothers Immune System May Block Fetal Treatments for Blood Diseases 54639 3Mothers Immune System May Block Fetal Treatments for Blood Diseases 54639 4Gaiam Announces New Deal With Valerie Bertinelli 54637 1Gaiam Announces New Deal With Valerie Bertinelli 54637 2Chewing Tobacco No Safer Than Smoking 54635 1Chewing Tobacco No Safer Than Smoking 54635 2
...e-FirstCall/ -- Shire plc,announced today the posi...ication guanfacine extended release (GXR,previous...renoceptor agonist. These data from two short-term...-term phase III,open-label studies, presented at t...ual meeting, demonstrated that GXR,significantly i...
...tudies with Monoclonal Antibody,Targeting Interleu...ionale for IL-9 Inhibition in Developing Potential... /PRNewswire-FirstCall/ --,MedImmune, Inc. today a...ent progress within the company,s inflammatory,dis...clinical,studies with its monoclonal antibody (MAb...
Other Medicine Technology:Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 2Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 3Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 4Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 5Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 6Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 7Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents 8MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 2MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 3MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 4MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 5MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 6MedImmune Highlights Advances in Inflammatory Disease Pipeline With,Series of Data Presentations 7
(Date:11/25/2009)...wswire/-SentinelleMedicalInc.,aleadingmanufacturer...unchesasuiteofnewleadingedgeclinicalapplicationson...ar,sRadiologicalSocietyofNorthAmerica(RSNA)annualm....Theapplicationsleveragetheuniquehighqualityimages...ndsupportmultipleimagingmodalitiesformulti-paramet...
(Date:11/25/2009).../PRNewswire/--TheBayAreaAirQualityManagementDistri... Air Alert forThursday,November26,2009whic...idfuel,bothindoorsandoutdoors. ,, "Cold,stillwe...saidJackBroadbent,executiveofficeroftheAirDistrict...heirneighborsandfellowcommunitymembersthisThanksgi...
(Date:11/25/2009)...that grew out of a collaboration between UCLA engi...to the nearly 10 million Americans who suffer from...s hardening of the arteries, peripheral arterial d... which narrowed arteries reduce blood flow to the ...vascular disease, heart attack and stroke, and its...
(Date:11/25/2009)...valuation and treatment clinics to resume Monday, ...s) November 25, 2009 -- Centegra Health System is ...accine shots at four Centegra Primary Care (CPC) v...ne has arrived. The clinics are at CPC sites in Hu...l be open as follows: ,   From 4:30 to...
(Date:11/25/2009)...wswire/-- MISSIONSkincare ®isproudtosupportGN...tofGNC,sannualSt.Jude ThanksandGiving campaign,$1f... SUPER-C(TM)LipBalm willbedonatedtoSt.Jude.Additio...$10donationatcheckoutatoneoftheir5,000+retaillocat...rSt.Judeduringtheir2009 ThanksandGiving campaign. ...
Breaking Medicine News(10 mins):Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 2Health News:Sentinelle Medical Launches Aegis Suite of Oncology 4D Visualization Software with PureWeb(TM) Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R) 2
...esota Clinic Fax Referral ...n., Sept. 25 Call it Quits,-- a newly named colla...ClearWay Minnesota(SM) -- is launching a new progr...al Program begins,October 1, just in time for the ...
...October 1; Join the Breast Cancer Mo...25 Celebrities ranging from TV stars to,sports he... breast cancer,a disease that without a cure could...s have pledged to make a difference in the war on ...
...me pioneering work which is the cellular equivalen...ick Tams 27-year exploration has mapped the moveme...bryos. It reveals how cells direct themselves to ...of the Childrens Medical Research Institute, was a...
...mited (ASX: PGL; Nasdaq: PGLA) announced today tha...een awarded Fast Track status by the U.S. Food,and...tion has been granted,to PI- 88 for the prevention...ation Act of 1997, the fast track program is,desig...
...ances in diabetes care, African Americans and Lati...their blood sugar under control, even with the hel...study finds. That puts them at a much higher risk ...ddle-aged and older adults, published in the Sept....
...effort to stem the rise of childhood obesity and r...lifornia (USC) has received a $7.5 million grant t...inority Health. This is USCs first major grant fro...nter is to understand why obesity and associated f...
Other Medicine News:Health News:Health Organizations Join Forces Around Quit-Smoking Help 2Health News:Celebrities Pledge to Wear Pink, End Breast Cancer Forever With Susan G. Komen for the Cure 2Health News:Celebrities Pledge to Wear Pink, End Breast Cancer Forever With Susan G. Komen for the Cure 3Health News:Explorer completes the map ... for the body's blueprint 2Health News:US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer 2Health News:US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer 3Health News:Older blacks and Latinos still lag whites in controlling diabetes 2Health News:Older blacks and Latinos still lag whites in controlling diabetes 3Health News:Older blacks and Latinos still lag whites in controlling diabetes 4Health News:Older blacks and Latinos still lag whites in controlling diabetes 5Health News:USC receives $7.5M for Comprehensive Center of Excellence in Minority Health 2
Illiterate 20' Test Chart
...ce recording unit suitable for a wide range of lif... 16 input channels. Examples include sleep, neurop... capable of recording at speeds of up to 200 000 s...patible with instruments, signal conditioners and ...
Three Figure Worth Type Test
Low Contrast Flip Chart with Lea Symbols
Medicine Products: